Notably, the correction of peripheral neutropenia observed in our CXCR2 LOF mice following CXCR4 antagonist treatment suggests a promising alternative for patients with CXCR2 LOF who do not adequately respond to G-CSF. This evidence concerns the gene CSF3 and neutropenia.